Eli Lilly and Company

🇺🇸New York Stock Exchange
Back to all articles
Eli Lilly and Company stock analysis LLY overview
Neutral 0

Eli Lilly (LLY) Laps the Stock Market: Here's Why - Yahoo Finance

📈 Eli Lilly shares closed up 1.82% at $1,008.39, outperforming the S&P 500's 0.83% gain.

📉 Despite recent gains, LLY stock has depreciated 6.41% over the past month.

🗓️ The company is scheduled to release its quarterly earnings report on April 30, 2026.

💰 Analysts project upcoming quarterly EPS of $7.5, representing a 124.55% year-over-year increase.

💵 Expected quarterly revenue is forecasted at $17.66 billion, up 38.75% from the prior quarter.

📊 Full-year earnings consensus estimates total $34.16 per share with a 41.1% year-over-year rise.

📉 Full-year revenue is projected at $81.93 billion, marking a 25.7% increase from last year.

📉 The Zacks Consensus EPS estimate has shifted 0.24% upward recently for the company.

⚖️ Eli Lilly currently holds a Zacks Rank of #3 (Hold) according to the investment model.

💰 LLY trades at a Forward P/E ratio of 29, significantly higher than the industry average of 15.83.

📈 The stock's PEG ratio is 1.17, which is lower than the Large Cap Pharmaceuticals industry average of 2.24.

🏭 The company belongs to the Medical sector, specifically within the Large Cap Pharmaceuticals industry.

📉 This industry group ranks #200 and sits in the bottom 19% echelon of all industries tracked.

📈 Top-rated industries historically outperform the bottom half by a factor of 2 to 1.

⚠️ Investors are advised to monitor analyst estimate revisions as they correlate with stock price performance.

Bullish Signals
  • Eli Lilly shares were up +1.82% at $1,008.39, outpacing the S&P 500's daily gain of 0.83%.
  • Analysts expect year-over-year earnings growth of 124.55%, with quarterly EPS estimated at $7.5.
  • Full-year Zacks Consensus Estimates project earnings of $34.16 per share, representing a +41.1% change from the prior year.
  • The company's projected full-year revenue of $81.93 billion represents a +25.7% increase from the prior year.
  • Eli Lilly is currently trading with a PEG ratio of 1.17, which is significantly lower than the industry average of 2.24, indicating value relative to growth.
  • The Zacks Consensus EPS estimate has shifted 0.24% upward recently, reflecting positive adjustments in analyst expectations.
Risk Factors
  • Eli Lilly's shares have depreciated by 6.41% over the past month, underperforming both the Medical sector (down 3.46%) and the S&P 500 (down 2.65%), indicating relative weakness despite positive market movements.
  • The stock is trading at a Forward P/E ratio of 29 compared to the industry average of 15.83, suggesting it is valued at a significant premium that could limit upside potential.
  • Eli Lilly's PEG ratio stands at 1.17 versus an industry average of 2.24, though this metric alone is neutral; however, the high P/E relative to peers remains a valuation risk.
  • The stock currently holds a Zacks Rank of #3 (Hold), indicating the analysis does not rate it as a strong buy opportunity at this time.
  • The Large Cap Pharmaceuticals industry ranks in the bottom 19% echelons among all 250+ industries, with top-rated sectors historically outperforming by a factor of 2 to 1, suggesting potential sector headwinds.
Full Analysis
Eli Lilly and Company (LLY) shares closed the session up 1.82% at $1,008.39, outperforming the S&P 500's gain of 0.83%, the Dow's 0.5%, and the Nasdaq's 1.38%. However, despite this daily gain, the stock has depreciated by 6.41% over the past month, underperforming both the Medical sector's loss of 3.46% and the S&P 500's loss of 2.65% during that period. The company is scheduled to release its earnings report on April 30, 2026, with analysts expecting earnings per share of $7.5, representing a year-over-year growth rate of 124.55%. For the full year, consensus estimates project earnings of $34.16 per share and revenue of $81.93 billion, which would reflect increases of 41.1% and 25.7%, respectively, from the prior year. The Q1 revenue is expected to reach $17.66 billion, a significant 38.75% increase from the previous quarter. Recent adjustments to analyst estimates show a 0.24% upward shift in consensus EPS over the past month, yet LLY currently holds a Zacks Rank of #3 (Hold) based on these revisions and business trends. In terms of valuation, Eli Lilly trades at a forward price-to-earnings ratio of 29 compared to an industry average of 15.83, indicating it is priced at a premium relative to its peers. The stock also holds a PEG ratio of 1.17 against an industry average of 2.24, suggesting better growth-adjusted value by that metric. The Large Cap Pharmaceuticals industry, in which LLY operates, holds a Zacks Industry Rank of 200 and is situated in the bottom 19% of all tracked industries, where research indicates that top-rated industries typically outperform the bottom half by a factor of 2 to 1. Investors are encouraged to monitor upcoming earnings and estimate revisions as these metrics have historically shown a direct relationship with future stock price performance.